Preclinical trials of new radiopharmaceuticals to treat ovarian cancer have been successful in dramatically limiting tumor growth and reducing tumor volume. Designed specifically for ovarian cancer that is resistant to conventional treatments, new radiopharmaceuticals can be manufactured in 25 minutes at low cost and are more efficient than other methods. This study was presented at the 2021 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.
According to the American Cancer Society, more than 20,000 women are diagnosed with ovarian cancer each year, and nearly 14,000 die from the disease. The 5-year survival rate for ovarian cancer patients is 49.1%. It is the fifth leading cause of cancer death in women.
In this study, researchers used a new generator system to develop targeted alpha therapy Pb-214-TCMC-trastuzumab to treat HER2-positive ovarian cancer.Mice with ovarian cancer cells and ovaries cancer Tumors were divided into three groups: a group treated with Pb-214-TCMC-trastuzumab, a group treated with Pb-214-TCMC-IgG, and an untreated control group. All groups were imaged over time to determine the effectiveness of the treatment.
Tumor signals in mice and cells treated with Pb-214-TCMC-trastuzumab were dramatically reduced during the course of the study, demonstrating therapeutic efficacy as compared to Pb-214-TCMC-IgG and the control group. It was.There was not Harmful side effects From treatment determined by weight loss in all living animals.
“Pb-214’s short half-life of 27 minutes is ideal for fractionation. Alpha particles Mike Zamiara, President and President of Niowave Inc., East Lansing, Michigan, said: In the future, this generator system will be available in many therapeutic products for turnkey systems under development, providing reliable doses for improving patient care.
Abstract 93. “Therapeutic Effect of Pb-214 Labeled Trastuzumab in Preclinical Models of Ovarian Cancer,” Abdullah Metebi, Comparative Medicine and Integrated Biology, Michigan State University, East Lansing, Michigan. Chelsea Nayback, Michigan State University, East Lansing, Michigan, Institute for Quantitative Health Science and Engineering. Ginda Fan, East Lansing, Michigan, Michigan State University, Institute for Quantitative Health Science and Engineering, Department of Radiation and Chemistry. Nathan Johnson, John Diemer, Terry Grimm, Mike Zamiara, Niowave, Inc., Lansing, Michigan. And Kurt Jin, East Lansing, Michigan, Michigan State University, Institute of Radiation and Quantitative Health Sciences and Engineering.
Provided by the Society of Nuclear Medicine and Molecular Imaging
Quote: Promising ovarian cancer treatment proved to be effective and efficient (11 June 2021) 11 June 2021, https://medicalxpress.com/news/2021-06- Obtained from ovarian-Cancer- Treatment-effective-efficient.html
This document is subject to copyright. No part may be reproduced without written permission, except for private research or fair trade for research purposes. The content is provided for informational purposes only.
Promising ovarian cancer treatments have proven to be effective and efficient
Source link Promising ovarian cancer treatments have proven to be effective and efficient